Dov Grossman’s practice focuses on intellectual property litigation, principally in the biopharmaceutical industry.  Dov’s educational background is in chemistry, including pre-clinical research, and he has relied on that experience to represent clients in multiple Hatch-Waxman cases, including as lead counsel.  In addition, Dov has advised clients in inter partes review proceedings involving pharmaceutical and biotech patents, as well as in disputes between innovator companies. 

Dov also has litigated matters in the medical device and telecommunications industries, and has advised clients on the negotiation of licensing agreements.

Dov currently serves as a member of the firm’s Associate Evaluation Committee.

Dov, who speaks Hebrew as well as English, grew up in Los Angeles.  Dov earned his J.D., with honors, from the University of Chicago, where he was articles editor for The University of Chicago Law Review and a member of the Order of the Coif.  Dov clerked for Judge William C. Bryson of the U.S. Court of Appeals for the Federal Circuit.  He received his A.B. in chemistry, magna cum laude, from Harvard University in 1997, and an M.Sc. in chemistry from the Weizmann Institute of Science in Israel.  Aspects of his Weizmann research were published in Letters in Peptide Science in 2002 (“Potentiating Vanadium-Evoked Glucose Metabolism by Novel Hydroxamate Derivatives”).  Dov joined Williams & Connolly in 2004.

Representative Experience

  • Serving as co-lead counsel in a Hatch-Waxman trial in the District of Delaware relating to Bayer’s erectile dysfunction medication vardenafil (marketed as Levitra® and Staxyn®).
  • Participating in four Hatch-Waxman trials related to Eli Lilly’s compound Alimta®, three on behalf of Lilly and one on behalf of Princeton University and Lilly.  Dov has also litigated multiple inter partes review proceedings related to Alimta®.
  • Representing AstraZeneca in litigation and co-pending inter partes review proceedings related to anti-diabetes treatments.
  • Representing Eli Lilly, Daiichi Sankyo, and Ube Industries in Hatch-Waxman litigation and co-pending inter partes review proceedings involving the anti-platelet medication Effient®.
  • Participating in a Hatch-Waxman trial involving the factor Xa inhibitor Xarelto®.
  • Participating in two Hatch-Waxman trials related to moxifloxacin, the antibiotic active ingredient in Bayer’s Avelox® product and Alcon’s Vigamox® eye drops.
  • Representing Bayer in Hatch-Waxman cases involving the anti-cancer medication Stivarga® and the anti-cancer medication Nexavar®.
  • Representing a client in a major international patent licensing arbitration, which was tried before a three-member panel.
  • Serving as lead outside counsel negotiating a portfolio cross-license agreement between suppliers of electronics components; and
  • Representing Alcon in Hatch-Waxman litigation involving Travatan Z® eye drops.



Government Service

Law Clerk, Judge William C. Bryson, United States Court of Appeals for the Federal Circuit, 2002-2003

back to top